Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020115223 - S100A4 AS A MARKER OF TREATMENT WITH SPIRONOLACTONE, PIOGLITAZONE AND METFORMIN

Publication Number WO/2020/115223
Publication Date 11.06.2020
International Application No. PCT/EP2019/083848
International Filing Date 05.12.2019
IPC
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Applicants
  • KATHOLIEKE UNIVERSITEIT LEUVEN [BE]/[BE]
  • HOSPITAL SANT JOAN DE DEU [ES]/[ES]
Inventors
  • DE ZEGHER, Francis
  • IBAÑEZ, Lourdes
Priority Data
1819876.205.12.2018GB
19177966.903.06.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) S100A4 AS A MARKER OF TREATMENT WITH SPIRONOLACTONE, PIOGLITAZONE AND METFORMIN
(FR) S100A4 UTILISABLE EN TANT QUE MARQUEUR DE TRAITEMENT PAR LA SPIRONOLACTONE, LA PIOGLITAZONE ET LA METFORMINE
Abstract
(EN)
The invention relates to the in vitro use of a ligand specifically binding to S100A4, such as antibody for identifying the response to treatment with spironolactone, pioglitazone and metformin, such as in PCOS patients. The invention further relates to an in vitro method for monitoring responsiveness of a subject to a treatment with spironolactone, pioglitazone and metformin, the method comprising: determining the concentration of S100A4 in a body sample obtained from the subject prior or at the onset of the treatment, determining the concentration of S100A4 in said body sample obtained from the subject during said treatment, wherein a decrease of S100A4 concentration compared to the concentration prior to or at the onset is indicative for an effective treatment.
(FR)
L'invention se rapporte à l'utilisation in vitro d'un ligand se liant de manière spécifique à S100A4, par exemple un anticorps pour identifier la réponse au traitement par la spironolactone, la pioglitazone et la metformine, par exemple chez des patientes souffrant d'un syndrome ovarien polykystique (SOP). L'invention concerne en outre un procédé in vitro de surveillance de la réactivité d'un sujet à un traitement par la spironolactone, la pioglitazone et la metformine, le procédé comprenant les étapes consistant à : déterminer la concentration en S100A4 d'un échantillon corporel prélevé chez le sujet avant le traitement ou au tout début de celui-ci, déterminer la concentration en S100A4 dudit échantillon corporel prélevé chez le sujet au cours dudit traitement, une baisse de la concentration en S100A4 par rapport à la concentration avant le traitement ou au tout début de celui-ci indiquant que le traitement est efficace.
Latest bibliographic data on file with the International Bureau